Andrea Henrich, Ph.D.
Senior Director, MIDD Consultant
Bio
- Joined Pharmetheus in 2020, actively working in client projects and serving as deputy Project Portfolio Team Leader
- Expertise includes QTc analysis, drug-drug interactions, and trial design in therapeutic areas such as oncology, cardiovascular, and immunology
- Previously worked as Modeling and Simulation Scientist at Idorsia Pharmaceuticals, Switzerland, where she performed population pharmacokinetic-pharmacodynamic analyses and concentration-QT modeling in different therapeutic areas
- Pharmacist (2013) from Johann-Wolfgang-Goethe-University, Germany, and Ph.D. in Clinical Pharmacy (2017) from Freie Universitaet Berlin, Germany
Pharmetheus affiliated publications
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on Phase I dataExposure-response analysis for time-to-event data in the presence of adaptive dosing: efficient approaches and pitfalls (Poster)Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuriaPharmacokinetic Characterization and Exposure-Response Relationship of Crovalimab in the COMPOSER and COMMODORE 3 Trials of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studiesThe Population PKPD of Unacylated and Acylated Ghrelin Following Single Rising Doses of BI 1356225 in Healthy Subjects is Impacted by the Time Since Last Meal